Overview

This trial is active, not recruiting.

Condition elevated lp(a)
Treatments ta-8995, placebo
Phase phase 1/phase 2
Sponsor Xention Ltd
Start date September 2014
End date February 2015
Trial size 42 participants
Trial identifier NCT02241772, TA-8995-06

Summary

A study in males and females with elevated Lp(a) to look at the effects of TA-8995 on Lp(a) levels.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose treatment
Arm
(Experimental)
10mg TA-8995 once daily
ta-8995
(Experimental)
2.5mg TA-8995 once daily
ta-8995
(Placebo Comparator)
Placebo to TA-8995 once daily.
placebo

Primary Outcomes

Measure
To evaluate the change from baseline in (Lp(a) levels after 12 weeks of treatment with TA-8995.
time frame: 12 weeks

Secondary Outcomes

Measure
Number of participants with adverse events
time frame: 12 weeks

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Male and female (of non-child bearing potential) subjects with elevated Lp(a) levels Exclusion Criteria: - Clinically significant medical history - Abnormal laboratory results (other than lipid levels) or vital signs - Receiving any other drug therapy

Trial information was received from ClinicalTrials.gov and was last updated in October 2014.
Information provided to ClinicalTrials.gov by Xention Ltd.